Define MAsS cut-point at transplant evaluation to identify those with high risk for adverse outcomes for Sarcopenia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mayo Clinic Arizona, Phoenix, AZ
Sarcopenia+5 More
MAsS - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.

Eligible Conditions

  • Sarcopenic Obesity
  • End Stage Liver DIsease
  • Sarcopenia
  • Cirrhosis of the Liver

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 1 year

1 year
Adverse outcomes
MAsS changes while waiting for liver transplant
Muscle assessment score (MAsS)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Define MAsS cut-point at transplant evaluation to identify those with high risk ...
1 of 1
Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: Define MAsS cut-point at transplant evaluation to identify those with high risk for adverse outcomes · No Placebo Group · N/A

Define MAsS cut-point at transplant evaluation to identify those with high risk for adverse outcomes
DiagnosticTest
Experimental Group · 1 Intervention: MAsS · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Trial Background

Prof. Elizabeth Carey, Professor of Medicine
Principal Investigator
Mayo Clinic
Closest Location: Mayo Clinic Arizona · Phoenix, AZ
Photo of mayo clinic arizona  1Photo of mayo clinic arizona  2Photo of mayo clinic arizona  3
2005First Recorded Clinical Trial
1 TrialsResearching Sarcopenia
147 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are an adult.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References